Mucovim (Acetylcysteine)

Acetylcysteine breaks disulfide bonds within mucus glycoproteins, which reduces the thickness and stickiness of mucus. This action lowers mucus viscosity, enhances mucociliary clearance, and makes it easier for patients to expectorate sputum during respiratory illnesses.

The appropriate dose of Mucovim is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and renal or hepatic function. Dosage regimens can vary, and the prescriber will provide specific instructions for each individual.

Safety data for acetylcysteine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Acetylcysteine, the active ingredient in Mucovim, is a thiol‑containing mucolytic that directly breaks disulfide bonds in mucus. Other agents such as carbocisteine or bromhexine work by altering mucus production or viscosity through different mechanisms. Acetylcysteine is often preferred for its rapid action and antioxidant properties.

Mucovim should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight. Keep the container tightly closed when not in use to maintain stability.

Mucovim is taken orally, usually as a tablet or liquid formulation, according to the prescriber’s directions. The dose may be taken with or without food, but patients should follow the specific instructions provided on the prescription label.

Serious risks include bronchospasm, especially in patients with active asthma, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Hepatic dysfunction and hemolysis in individuals with G6PD deficiency have also been reported. Any signs of these reactions require immediate medical attention.

Mucovim should be avoided in individuals with known hypersensitivity to acetylcysteine or any of its excipients. Patients with severe bronchospasm, uncontrolled asthma, or those who have experienced serious allergic reactions to mucolytics should not use this product without close medical supervision.